Effectiveness of Vitamin B2 versus Sodium Valproate in Migraine Prophylaxis
A randomized clinical trial
Keywords:
migraine, sodium valproate, vitamin B2Abstract
Background: Migraine headache is a prevalent periodical and neurological impairment that is associated with functional disorders. Regarding the side effects of available medications, research is continuing in an effort to identify new, effective pharmaceutical regimens with limited side effects.
Objective: The aim of this study was to compare the effectiveness of vitamin B2 versus sodium valproate in migraine prophylaxis.
Methods: This was a single-blind clinical trial conducted on 90 migraine patients in two parallel groups. The first group underwent vitamin B2 treatment (400 mg/day) for three months, and the second group was treated with sodium valproate (500 mg/day). The patients were examined at the beginning of the study and 4, 8, and 12 weeks later. After the administration of the drugs in both groups, we recorded the duration of migraine pain, the frequency of migraine episodes, and the severity of the headaches. Potential complications of this study that were measured were weight gain, dizziness, and gastrointestinal problems.
Results: The findings showed that the frequency, median duration per month, and severity of the headaches decreased in both groups, but the difference between them was not significant (p > 0.05). However, there were significantly fewer side effects in vitamin B2 group (p = 0.005).
Conclusion: Sodium valproate and vitamin B2 have similar effects on the reduction of migraine attacks, but vitamin B2 had fewer complications and fewer adverse effects; therefore, vitamin B2 can be administered to patients who are prohibited from taking sodium valproate or who have adverse side effects when they take it.
Trial registration: The trial is registered at the Thailand Clinical Trial Registry (http://www.clinicaltrials.in.th) with the TCTR identification number TCTR20150924001.
Funding: This study received no funding from external sources.
References
Togha M, Rahmat M, Nilavary K, Ashrafian H, Razeghi S. Efficacy of Cinnarizine and Sodium Valproate
in migraine prophylaxis: a clinical trial. Tehran University Medical Journal. 2006;64(6):121-30.
Longo D, Fauci A, Kasper D, Hauser S. Harrison's Principles of Internal Medicine 18th edition: McGraw- Hill Professional; 2011.
Ropper AH. Adams and Victor's principles of neurology: McGraw-Hill Medical New York; 2009
Rozen T, Oshinsky M, Gebeline C, Bradley K, Young W, Shechter A, et al. Open label trial of coenzyme
Q10 as a migraine preventive. Cephalalgia. 2002;22(2):137-41. doi: 10.1046/j.1468-2982.2002.00335.x,
PMid: 11972582
Sandor P, Di Clemente L, Coppola G, Vandenheede M, Fumal A, Agosti R, et al., editors. A randomized
controlled trial of coenzyme Q10 in migraine prophylaxis. Neurology; 2004: LIPPINCOTT WILLIAMS &
WILKINS 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
Kunsman GW, Levine B, Smith ML. Vitamin B~ 2 Interference with TDx Drugs-of-Abuse Assays. Journal
of forensic sciences. 1998;43:1225-7, doi: 10.1520/JFS14390J. PMid: 9846401
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the
United States: data from the American Migraine Study II. Headache. 2001;41(7):646-57. doi:
1046/j.1526-4610.2001.041007646.x, PMid: 11554952
Göbel H, Heinze A, Heinze-Kuhn K. [Prophylactic measures and acute treatment of migraine]. Schmerz
(Berlin, Germany). 2006;20(6):541-54; quiz 55-6, doi: 10.1046/j.15264610.2001.041007638.x. PMid:
Sándor PS, Áfra J, Ambrosini A, Schoenen J. Prophylactic Treatment of Migraine With β‐Blockers and
Riboflavin: Differential Effects on the Intensity Dependence of Auditory Evoked Cortical Potentials.
Headache: The Journal of Head and Face Pain. 2000;40(1):30-5, doi: 10.1046/j.1526-4610.2000.00005.x.
PMid:10759900
Matson JL, Bamburg JW, Mayville EA, Pinkston J, Bielecki J, Kuhn D, et al. Psychopharmacology and
mental retardation: a 10 year review (1990-1999). Research in developmental disabilities. 2000;21(4):263- 96. doi: 10.1016/S0891-4222(00)00042-1
Raymond D. Adams RD, Victor M, Principle of neurology. New York Mc Graw Hill; 1993.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl j Med.
;346(4):257-70, doi: 10.1056/NEJMra010917. PMid:11807151
Freitag F, Collins S, Carlson H, Goldstein J, Saper J, Silberstein S, et al. A randomized trial of divalproex
sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58(11):1652-9, doi:
1212/WNL.58.11.1652. PMid: 12058094
Published
Issue
Section
License
Copyright (c) 2020 knowledge kingdom publishing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
